LVTX: Insider sells at $1.53–$1.62; holds 5,294,178 shares

LAVA Therapeutics NV (LVTX) reported insider sales by affiliated reporting persons.

Rhea-AI Filing Summary

LAVA Therapeutics NV (LVTX) reported insider sales by affiliated reporting persons. On 10/08/2025, they sold 28,954 common shares at a weighted average price of $1.57 (range $1.56–$1.62). On 10/09/2025, they sold 48,169 shares at $1.56 (range $1.54–$1.59). On 10/10/2025, they sold 49,869 shares at $1.55 (range $1.53–$1.58).

Following these transactions, beneficial ownership reported as direct stood at 5,392,216, then 5,344,047, and finally 5,294,178 shares. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A.; related entities Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V. disclaim beneficial ownership except to the extent of their pecuniary interests.

Insider Trade Summary

Net Seller: 126,992 shares

Net Sell 3 txns

Insider Cooperatieve Gilde Healthcare IV U.A., Gilde Healthcare Holding B.V.

Role 10% Owner | 10% Owner

Sold 126,992 shs ($198K)

Type	Security	Shares	Price	Value
Sale	Common Shares	49,869	$1.55	$77K
Sale	Common Shares	48,169	$1.56	$75K
Sale	Common Shares	28,954	$1.57	$45K

Holdings After Transaction: Common Shares — 5,294,178 shares (Direct)

Footnotes (4)

1. F1. This figure is the weighted average sales price of multiple trades ranging from $1.56 to $1.62 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
2. F2. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein.
3. F3. This figure is the weighted average sales price of multiple trades ranging from $1.54 to $1.59 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
4. F4. This figure is the weighted average sales price of multiple trades ranging from $1.53 to $1.58 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

FAQ

Which LVTX insider reported the transactions?

The shares are held directly by Cooperatieve Gilde Healthcare IV U.A., with Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V. as additional reporting persons.

How many LVTX shares were sold on 10/08/2025 and at what price?

28,954 common shares were sold at a weighted average price of $1.57 per share, within a range of $1.56–$1.62.

What LVTX sales occurred on 10/09/2025?

A sale of 48,169 common shares at a weighted average price of $1.56, within a range of $1.54–$1.59.

What LVTX sales occurred on 10/10/2025?

A sale of 49,869 common shares at a weighted average price of $1.55, within a range of $1.53–$1.58.

What was the LVTX beneficial ownership after these transactions?

Reported direct beneficial ownership was 5,392,216 shares after 10/08/2025, 5,344,047 after 10/09/2025, and 5,294,178 after 10/10/2025.

What relationship to LVTX is indicated for the reporting person?

The form indicates the reporting person is a Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/10/2025 - 06:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooperatieve Gilde Healthcare IV U.A.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/08/2025		S		28,954	D	$1.57(1)	5,392,216	D(2)
Common Shares	10/09/2025		S		48,169	D	$1.56(3)	5,344,047	D(2)
Common Shares	10/10/2025		S		49,869	D	$1.55(4)	5,294,178	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Cooperatieve Gilde Healthcare IV U.A.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Gilde Healthcare Holding B.V.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This figure is the weighted average sales price of multiple trades ranging from $1.56 to $1.62 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

2. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein.

3. This figure is the weighted average sales price of multiple trades ranging from $1.54 to $1.59 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

4. This figure is the weighted average sales price of multiple trades ranging from $1.53 to $1.58 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

	Cooperatieve Gilde Healthcare IV U.A., By: /s/ Edwin de Graaf, Managing Director	10/10/2025
	Gilde Healthcare IV Management B.V., By: /s/ Edwin de Graaf, Managing Director	10/10/2025
	Gilde Healthcare Holding B.V., By: /s/ Edwin de Graaf, Managing Director	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.